vs
Side-by-side financial comparison of ZW Data Action Technologies Inc. (CNET) and Inhibikase Therapeutics, Inc. (IKT). Click either name above to swap in a different company.
ZW Data Action Technologies Inc. is the larger business by last-quarter revenue ($1.7M vs $1.0M, roughly 1.6× Inhibikase Therapeutics, Inc.). ZW Data Action Technologies Inc. runs the higher net margin — -6.3% vs -1223.3%, a 1217.0% gap on every dollar of revenue.
ZW Data Action Technologies Inc., trading under the symbol CNET, is a China-based technology enterprise focused on delivering integrated digital marketing solutions, big data analysis services, and intelligent operation tools for enterprise clients across sectors including e-commerce, consumer goods, and internet services. Its offerings help clients optimize user acquisition efficiency, boost operational performance, and advance digital transformation, primarily serving the Chinese domestic market and select Asia-Pacific clients.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
CNET vs IKT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7M | $1.0M |
| Net Profit | $-108.0K | $-12.7M |
| Gross Margin | 5.7% | — |
| Operating Margin | -8.9% | -1323.3% |
| Net Margin | -6.3% | -1223.3% |
| Revenue YoY | -47.0% | — |
| Net Profit YoY | 94.4% | -5.0% |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0M | ||
| Q3 25 | $1.7M | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | $1.7M | $0 | ||
| Q4 24 | $2.2M | $0 | ||
| Q3 24 | $3.2M | $0 | ||
| Q2 24 | $6.4M | $0 | ||
| Q1 24 | $3.5M | $0 |
| Q4 25 | — | $-12.7M | ||
| Q3 25 | $-108.0K | $-11.9M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | $-531.0K | $-13.7M | ||
| Q4 24 | $-781.0K | $-12.1M | ||
| Q3 24 | $-1.9M | $-5.8M | ||
| Q2 24 | $-216.0K | $-5.0M | ||
| Q1 24 | $-850.0K | $-4.6M |
| Q4 25 | — | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | -0.4% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | -1323.3% | ||
| Q3 25 | -8.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -35.0% | — | ||
| Q4 24 | -24.1% | — | ||
| Q3 24 | -61.5% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -26.1% | — |
| Q4 25 | — | -1223.3% | ||
| Q3 25 | -6.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -32.1% | — | ||
| Q4 24 | -34.7% | — | ||
| Q3 24 | -59.1% | — | ||
| Q2 24 | -3.4% | — | ||
| Q1 24 | -24.1% | — |
| Q4 25 | — | $-0.10 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | — | $-0.65 | ||
| Q2 24 | — | $-0.66 | ||
| Q1 24 | — | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.3M | $172.9M |
| Total Assets | $9.7M | $181.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $218.3M | ||
| Q3 25 | $1.8M | $39.1M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | $807.0K | $19.7M | ||
| Q4 24 | $812.0K | $138.6M | ||
| Q3 24 | $1.1M | $2.3M | ||
| Q2 24 | $510.0K | $4.9M | ||
| Q1 24 | $467.0K | $7.4M |
| Q4 25 | — | $172.9M | ||
| Q3 25 | $3.3M | $72.9M | ||
| Q2 25 | — | $80.1M | ||
| Q1 25 | $3.1M | $85.7M | ||
| Q4 24 | $3.7M | $94.9M | ||
| Q3 24 | $4.8M | $-530.6K | ||
| Q2 24 | $5.2M | $5.1M | ||
| Q1 24 | $5.4M | $6.8M |
| Q4 25 | — | $181.2M | ||
| Q3 25 | $9.7M | $79.6M | ||
| Q2 25 | — | $88.9M | ||
| Q1 25 | $9.5M | $94.3M | ||
| Q4 24 | $9.7M | $98.6M | ||
| Q3 24 | $11.0M | $4.4M | ||
| Q2 24 | $10.8M | $8.8M | ||
| Q1 24 | $11.4M | $11.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-482.0K | $-7.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.5M | ||
| Q3 25 | $-482.0K | $-10.6M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | $-984.0K | $-4.1M | ||
| Q4 24 | $-830.0K | $-5.3M | ||
| Q3 24 | $-198.0K | $-4.9M | ||
| Q2 24 | $-677.0K | $-5.1M | ||
| Q1 24 | $-353.0K | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.0M | $-4.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -61.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CNET
| Online Advertising Placement | $1.6M | 95% |
| Other | $83.0K | 5% |
IKT
Segment breakdown not available.
